Negative / Null Result ReportOpen accessMedicine· cited by 12

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy

Akram I. Ahmad; Samita Garg; Jeffrey Jacobs; Zaid Ansari; Tasneem Jamal Al-Din; Ashraf Ali Ahmad Almomani; Sara Osorio Valencia; John J. Vargo · 2026 · JAMA Internal Medicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Importance: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are known to increase the risk of retained gastric contents. High-quality data are lacking to guide periprocedure management of GLP-1 and GIP agonists. Objective: To compare the risk of clinically significant residual gastric volume (RGV) in patients who continue vs hold 1 dose of weekly or daily GLP-1 and GIP agonists prior to sedation. Design, Setting, and Participants: This randomized, single-masked clinical trial conducted at 2 large tertiary referral centers in the US included patients under

Abstract by Akram I. Ahmad; Samita Garg; Jeffrey Jacobs; Zaid Ansari; Tasneem Jamal Al-Din; Ashraf Ali Ahmad Almomani; Sara Osorio Valencia; John J. Vargo, JAMA Internal Medicine (2026) — licensed CC BY 4.0.

Read the full paper (open access)